and Michio, U., Endocrinology, 97, 352
(1975).
2. Yajima, M. et al., J. Biochem., 83, 295 (1978).
3. Sekura, R.D. et al., J. Biol. Chem., 258, 14647-
14651 (1983).
4. Arai, H. and Sato, Y., Biochim
control or supplier information.
3. Rakieten, N. et al., Cancer Chemother. Reports, No. 29, 91-98 (1963).
4. Martindale: The Extra Pharmacopoeia, 29th ed., (Pharmaceutical Press, 1989), p. 649.
5. Burcelin
Predominant and extrasynaptic localization
in dendritic spines. Proc. Natl. Acad. Sci USA, 91,
5720-5724 (1994).
4. Yung, K.K.L., et al., Immunocytochemical
localization of D1 and D2 dopamine receptors
for at least
6 months at 4 °C. Solutions at pH 7.0, were reported to
remain active up to 50 °C for 15 minutes.13
References
1. Sumi, T. and Michio, U., Endocrinology, 97, 352
(1975).
2. Yajima
Invest.,
21, Suppl. 97, 77-89 (1968)
2. Boyum, A., Isolation and removal of lymphocytes
from bone marrow of rats and guinea-pigs., Scand
J. Clin. Lab. Invest., 21, Suppl.97, 91-109 (1968).
3.
Sci. USA, 91, 2305-2309 (1994).
3. Tashiro, K. et al., Signal sequence trap: a cloning
strategy for secreted proteins and type I membrane
proteins. Science, 261, 600-603 (1993).
4. Bleul, C
. Sci. USA, 91, 2305-2309 (1994).
3. Tashiro, K. et al., Signal sequence trap: a cloning
strategy for secreted proteins and type I membrane
proteins. Science, 261, 600-603 (1993).
4. Oberlin, E.
Acad. Sci. USA, 87, 6934
(1990).
3. Gearing, D.P., et al., Proc. Natl. Acad. Sci. USA, 91,
1119 (1994).
4. Pennica, D., et al., J. Biol. Chem., 270, 10915
(1995).
5. Kitamura, T., et
Enabling and Disabling parts:
No parts to disable.
N
N Boc
N
OH
HO
N
91%
(salt: HCl)
91%
(salt: HCl)
N
N
H
Cl
87%
(salt: TsOH)
OHS
HN
O
95%
(salt: HCl)
Acad. Sci.
USA, 91, 5109 (1994).
2. Keane, J., et al., J. Immunol., 160, 5945 (1998).
ProductInformation
3. Cruikshank, W.W., et al., J. Immunol., 146, 2928
(1991).
4. Baier, M., et al
FEBS Lett., 270, 216-218
(1990).
3. Ohuchi, K., et al., Biochim. Biophys. Acta, 1013,
86-91 (1989).
4. Suganuma, M. et al., Proc. Natl. Acad. Sci. USA,
85, 1768-1771 (1988).
5. Mistry, S.J., et
FEBS Lett., 270, 216-218
(1990).
3. Ohuchi, K. et al., Biochim. Biophys. Acta, 1013, 86-
91 (1989).
4. Suganuma, M. et al., Proc. Natl. Acad. Sci. USA,
85, 1768-1771 (1988).
5. Mistry, S.J. et
FEBS Lett., 270, 216-218
(1990).
3. Ohuchi, K., et al., Biochim. Biophys. Acta, 1013,
86-91 (1989).
4. Suganuma, M. et al., Proc. Natl. Acad. Sci. USA,
85, 1768-1771 (1988).
5. Mistry, S.J., et
1972).
2. Emmet, Y., et al., Acta Endocrin., 69, 567 (1972).
3. Wu, C., and L. Lundy, Steroids, 18, 91 (1971).
* Each vial contains no more than 20 mg Polyvi-
nylpyrrolidone (PVP). Due to the PVP and